Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias.
One hundred patients with involuntary eyelid and facial spasms resulting from essential blepharospasm, Meige syndrome, and hemifacial spasm continued to respond to repeated injections of botulinum toxin at expected time intervals during a 30-month period. This series of more than 372 injections done by one of us (JAM) supports the finding of earlier, smaller series that tolerance to the toxin does not develop. The drug had a greater duration of effect in patients with hemifacial spasm than in patients with blepharospasm; the duration of effect was 17.25 weeks in the former group and 12.6 weeks in the latter. Eighteen percent of patients required a higher than standard dose for a therapeutic response. Fourteen of 15 patients with lower facial spasms and one patient with torticollis had significant relief. Dry eye may be managed by titrating the lower lid dose.
Mauriello
J A
JA
Department of Ophthalmology, UMDNJ-New Jersey Medical School, Eye Institute of New Jersey, Newark 07107.
Coniaris
H
H
Haupt
E J
EJ
D001764:Blepharospasm / Q000188:drug therapy*; D001905:Botulinum Toxins / Q000627:therapeutic use*; D005141:Eyelid Diseases / Q000188:drug therapy*; D005152:Facial Muscles; D006801:Humans; D008538:Meige Syndrome / Q000188:drug therapy; D009069:Movement Disorders / Q000188:drug therapy*; D013035:Spasm / Q000188:drug therapy*
D001905:Botulinum Toxins